Evidence map›Paper›PMID 39553459›Full record

ArticleInternational journal of nanomedicine2024

Dextran-Graft-Polyacrylamide/Zinc Oxide Nanoparticles Inhibit of Cancer Cells in vitro and in vivo.

Petro Virych, Pavlo Virych, Volodymyr Prokopiuk, Anatolii Onishchenko, Mykola Ischenko, Volodymyr Doroschuk, Valentyna Kurovska, Anton Tkachenko, Nataliya Kutsevol

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Petro VirychLaboratory of Mechanisms of Drug Resistance, R.E. Kavetsky Institute for Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine.
Pavlo VirychFaculty of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.ORCID 0000-0002-1463-1992
Volodymyr ProkopiukResearch Institute of Experimental and Clinical Medicine, Kharkiv National Medical University, Kharkiv, Ukraine.
Anatolii OnishchenkoResearch Institute of Experimental and Clinical Medicine, Kharkiv National Medical University, Kharkiv, Ukraine.
Mykola IschenkoFaculty of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.ORCID 0000-0002-0851-1679
Volodymyr DoroschukFaculty of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Valentyna KurovskaEducational and Scientific Center "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Anton TkachenkoDepartment of Cryobiochemistry, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine.ORCID 0000-0002-1029-1636
Nataliya KutsevolFaculty of Chemistry, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Tumor drug resistance and systemic toxicity are major challenges of modern anticancer therapy. Nanotechnology makes it possible to create new materials with the required properties for anticancer therapy. Methods: In this research, Dextran-graft-Polyacrylamide/ZnO nanoparticles were used. The study was carried out using prostate (DU-145, LNCaP, PC-3), breast (MDA-MB-231, MCF-7, MCF-7 Dox) cancer cells and non-malignant (MAEC, BALB/3T3 clone A31) cells. Zinc was visualized with fluorescence in vitro and in vivo. ROS and apoptotic markers were identified by cytometry. Zinc accumulation and histopathological changes in the tumor, liver, kidney, and spleen were evaluated in a rat model. Results: ZnO nanoparticles dissociation and release of Zn Conclusion: D-PAA/ZnO NPs nanosystems were internalized by prostate, breast cancer cells and non-malignant cells via endocytosis after short time, but cytotoxicity against non-cancer cells were significantly lower in vitro and in vivo. D-PAA/ZnO NPs nanocomplex efficiently promoted cell death of tumor cells without showing cytotoxicity against non-malignant cells making it a promising anti-cancer agent.

Indexed as

Acrylic ResinsDextransZinc OxideAnimalsAntineoplastic AgentsApoptosisCell Line, TumorDoxorubicinFemaleHumansMaleMCF-7 CellsMetal NanoparticlesMiceNanoparticlesPolyacrylamidesAcrylic ResinsAntineoplastic AgentsDextransDoxorubicinPolyacrylamidesReactive Oxygen SpeciesZinc Oxidebreast cancerdoxorubicinhistopathologyprostate cancerzinc imagingzinc oxide nanoparticles

Identifiers

PMID39553459
PMCPMC11566607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.